3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 10, 2010, Pages 3129-3133

  Brnardic, Edward J ^a   Fraley, Mark E ^a   Garbaccio, Robert M ^a   Layton, Mark E ^a   Sanders, John M ^a   Culberson, Chris ^a   Jacobson, Marlene A ^a   Magliaro, Brian C ^a   Hutson, Pete H ^a   O'Brien, Julie A ^a   Huszar, Sarah L ^a   Uslaner, Jason M ^a   Fillgrove, Kerry L ^a   Tang, Cuyue ^a   Kuo, Yuhsin ^a   Sur, Sylvie M ^a   Hartman, George D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hit to lead; Metabotropic glutamate receptors; mGluR2; Oxazolidinone; Positive allosteric modulator; Schizophrenia

Indexed keywords

4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 5 HEXYL 3 PHENYL 1,3 OXAZOLIDIN 2 ONE; METABOTROPIC RECEPTOR 2; NEUROLEPTIC AGENT; OXAZOLIDIONE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIPOPHILICITY; NONHUMAN; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; KETAMINE; OXAZOLIDINONES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 77952100973     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.089     Document Type: Article

References (25)

1. Regier D.A., Narrow W.E., Rae D.S., Manderscheid R.W., Locke B.Z., and Goodwin F.K. Arch. Gen. Psychiatry 50 (1993) 85
2. Tandon R., Keshavan M.S., and Nasrallah H.A. Schizophr. Res. 100 (2008) 4
3. Tandon R., Keshavan M.S., and Nasrallah H.A. Schizophr. Res. 102 (2008) 1
4. Murphy B.P., Chung Y.C., Park T.W., and McGorry P.D. Schizophr. Res. 88 (2006) 5
5. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. N. Eng. J. Med. 353 (2005) 1209
6. Chavez-Noriega L.E., Schaffhauser H., and Campbell U.C. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 261
7. Conn P.J., Tamminga C., Schoepp D.D., and Lindsley C. Mol. Interventions 8 (2008) 99
8. Schoepp D.D. J. Pharmacol. Exp. Ther. 299 (2001) 12
9. Moghaddam B., and Adams B.W. Science 281 (1998) 1349
10. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Scheopp D.D. Nat. Med. 13 (2007) 1102
11. Cube R.V., Vernier J.M., Hutchinson J.H., Gardner M.F., James J.K., Rowe B.A., Schaffhauser H., Daggett L., and Pinkerton A.B. Bioorg. Med. Chem. Lett. 14 (2005) 2389 and references cited therein
12. Sandeep T.P., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Nat. Med. 13 (2007) 1102 and references cited therein
13. Duplantier A.J., Efremov I., Candler J., Doran A.C., Ganong A.H., Haas J.A., Hanks A.N., Kraus K.G., Lazzaro J.T., Lu J., Maklad N., McCarthy S.A., O'Sullivan T.J., Rogers B.N., Siuciak J.A., Spraklin D.K., and Zhang L.B. Bioorg. Med. Chem. Lett. 19 (2009) 2524
14. Fraley M.E. Exp. Opin. Ther. Patent 19 (2009) 1259
15. Pin J.P., Parmentier M.L., and Prezeau L. Mol. Pharmacol. 60 (2001) 881
16. Iwakura Y., and Izawa S.I. J. Org. Chem. 29 (1964) 379
17. Fujimoto Y., Suzuki Y., Tanaka Y., Tominaga T., Takeda H., Sekine H., Morito N., and Miyaoka Y. Heterocycles 6 (1977) 1604
18. Mallesham B., Rajesh B.M., Reddy P.R., Srinivas D., and Trehan S. Org. Lett. 5 (2003) 963
19. 20 concentration of glutamate to measure potentiation. The peak of the calcium response was used to construct concentration-response curves.
20. Schaffhauser H., Rowe B.A., Morales S., Chaves-Noriega L.E., Yin R., Jachec C., Rao S.P., Bain G., Pinkerton A.B., Vernier J., Bristow L.J., Varney M.A., and Daggett L.P. Mol. Pharmacol. 64 (2003) 798
21. Jin C.Z., Hagasawa H., Shimamura M., Uto Y., Inayama S., Takeuchi Y., Kirk K.L., and Hori H. Bioorg. Med. Chem. 12 (2004) 4917
22. Wu H.Y., Ding J.C., and Liu Y.K. J. Indian Chem. Soc. 80 (2003) 36
23. Schoepp D.D., and Marek G.J. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 215
24. Adult male Wistar Hannover rats weighing 200-250 g were transported to the testing room, administered compound 34 (30 or 100 mg/kg; ip), LY379268 (10 mg/kg; ip) or vehicle (PEG 400) and placed in locomotor activity monitors (43.2 cm × 43.2 cm Med Associates activity chamber; each apparatus was housed in a sound attenuating chamber). After habituation to the activity monitors for 30 min, animals were given an injection of ketamine (37.5 mg/kg; s.c.) and monitored for an additional 60 min.
25. Brnardic, E.; Fraley, M.; Garbaccio, R.; Layton, M.; PCT Int. Patent Appl. WO 2009/094265.